

Educational Symposium on Axial Spondyloarthritis and Psoriatic Arthritis
Tuesday, November 15, 2022 | 7:00 – 9:30 AM
 Philadelphia Marriott Downtown

7:00 – 7:30 AM Registration and Breakfast

7:30 – 7:40 AM **Welcome and Pre-test Questions**

Mohamad Bittar, MD
 Assistant Professor of Medicine
 UT Health Sciences Center
 Memphis, Tennessee

Soha Dolatabadi, MD
 Rheumatology Specialist
 Los Angeles, California

7:40 – 8:05 AM **AxSpA Year in Review**

Marina Magrey, MD
 Professor of Medicine
 Case Western Reserve University School of Medicine
 Division Chief of Rheumatology for University Hospitals
 Cleveland, Ohio

8:05 – 8:30 AM **PsA Year in Review**

Alexis Ogdie, MD, MCSE
 Associate Professor of Medicine and Epidemiology
 Perelman School of Medicine
 Director of the Penn Psoriatic Arthritis and Spondyloarthritis Program
 University of Pennsylvania
 Philadelphia, Pennsylvania

8:30 – 8:55 AM **Difficult-to-treat Spondyloarthritis: Does It Exist?**

Filip van den Bosch, MD, PhD
 Head-of-Clinic and Associate Professor of Rheumatology
 Department of Rheumatology
 University Hospital of Ghent University

8:55 - 9:20 AM **JAKi safety – Application of Existing Data to PsA/AxSpA**

Jack Cush, MD
 Executive Editor
 Rheum Now

9:20 – 9:30 AM **Post-test and Conclusion**

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of OHSU School of Medicine. The OHSU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Target Audience

Rheumatologists, PAs, and ARNPs.

Credit: OHSU School of Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

After participating in the CME Activity, the learner will:

1. Be kept up-to-date with recent advancements in the fields of axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA).
2. Be able to recognize the challenges in evaluating and managing cases of refractory spondyloarthritis.
3. Understand the safety concerns of JAK inhibitors as they relate to axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA)